Comedication with corticosteroids and nonsteroidal antiphlogistics does not affect PD-L1 expression in non-small cell lung cancer.
Non-small cell lung cancer (NSCLC)
corticosteroids
lung cancer
non-steroidal anti-inflammatory drugs (NSAIDs)
programmed death-ligand 1 (PD-L1)
Journal
Translational cancer research
ISSN: 2219-6803
Titre abrégé: Transl Cancer Res
Pays: China
ID NLM: 101585958
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
07
02
2022
accepted:
18
07
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
15
10
2022
Statut:
ppublish
Résumé
Programmed death-ligand 1 (PD-L1) expression is a standard predictor in the selection of immunotherapy for locally advanced/advanced non-small cell lung cancer (NSCLC). However, comedication with corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs) may influence the effectiveness of this treatment as documented in several previous studies. Due to certain molecular linkages between PD-L1 and corticosteroids or NSAIDs, we therefore addressed the question of whether there is a relationship between PD-L1 expression in NSCLC and the use of this comedication. This is a retrospective study using the Czech tumor registry LUng CAncer focuS (LUCAS), from which patient data were drawn. Independence of two categorical parameters was tested by Pearson's chi-square test. In our group of 1,148 patients, we observed no significant relationship between PD-L1 expression and the use of corticosteroids or NSAIDs. According to our data, treatment with corticosteroids or NSAIDs during biopsy does not affect the expression of PD-L1 and it is therefore not necessary to take this treatment into account in this regard.
Sections du résumé
Background
UNASSIGNED
Programmed death-ligand 1 (PD-L1) expression is a standard predictor in the selection of immunotherapy for locally advanced/advanced non-small cell lung cancer (NSCLC). However, comedication with corticosteroids or non-steroidal anti-inflammatory drugs (NSAIDs) may influence the effectiveness of this treatment as documented in several previous studies. Due to certain molecular linkages between PD-L1 and corticosteroids or NSAIDs, we therefore addressed the question of whether there is a relationship between PD-L1 expression in NSCLC and the use of this comedication.
Methods
UNASSIGNED
This is a retrospective study using the Czech tumor registry LUng CAncer focuS (LUCAS), from which patient data were drawn. Independence of two categorical parameters was tested by Pearson's chi-square test.
Results
UNASSIGNED
In our group of 1,148 patients, we observed no significant relationship between PD-L1 expression and the use of corticosteroids or NSAIDs.
Conclusions
UNASSIGNED
According to our data, treatment with corticosteroids or NSAIDs during biopsy does not affect the expression of PD-L1 and it is therefore not necessary to take this treatment into account in this regard.
Identifiants
pubmed: 36237267
doi: 10.21037/tcr-22-260
pii: tcr-11-09-3017
pmc: PMC9552102
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3017-3023Informations de copyright
2022 Translational Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-22-260/coif). M Svaton received honoraria by Astra Zeneca, Roche, MSD, BMS, Takeda, Novartis (consulting fees, lectures, Advisory Boards) and also is supported by academic institutional grant. M Bratova had presentations and lectures for BMS, MSD and Astra Zeneca in last 36 months. The other authors have no conflicts of interest to declare.
Références
Med Sci Monit. 2011 May;17(5):BR125-31
pubmed: 21525800
Oncogene. 2021 Aug;40(31):5002-5012
pubmed: 34175886
Prostaglandins Leukot Med. 1985 Sep;19(3):289-300
pubmed: 3864170
PLoS One. 2015 Apr 06;10(4):e0123410
pubmed: 25844720
BMC Cancer. 2020 Dec 3;20(1):1185
pubmed: 33272262
J Clin Oncol. 2018 Oct 1;36(28):2872-2878
pubmed: 30125216
Carcinogenesis. 2019 Feb 4;:
pubmed: 30715244
J Pharmacol Exp Ther. 2019 Mar;368(3):401-413
pubmed: 30591531
Anticancer Res. 2020 Apr;40(4):2209-2217
pubmed: 32234916
Thorac Cancer. 2020 Jun;11(6):1587-1593
pubmed: 32297484
Eur J Immunol. 2009 Nov;39(11):3147-59
pubmed: 19688742
Cells. 2021 Sep 06;10(9):
pubmed: 34571982
Anticancer Res. 2018 Aug;38(8):4637-4644
pubmed: 30061230
Blood. 2010 Aug 19;116(7):1124-31
pubmed: 20472834
Pharmacol Res. 2016 Dec;114:67-73
pubmed: 27777130
J Transl Med. 2017 Feb 23;15(1):46
pubmed: 28231855
Cytotherapy. 2013 Jun;15(6):740-9
pubmed: 23643305
J Natl Compr Canc Netw. 2021 Mar 02;19(3):254-266
pubmed: 33668021
Blood. 2006 Mar 1;107(5):2037-44
pubmed: 16293609
Clin Cancer Res. 2013 Feb 1;19(3):598-609
pubmed: 23095323
Cancer Prev Res (Phila). 2022 Apr 1;15(4):225-231
pubmed: 34987061
Int J Mol Sci. 2014 Jun 18;15(6):11013-29
pubmed: 24945311
Biochem Biophys Res Commun. 2005 Apr 29;330(1):263-70
pubmed: 15781259
Cancer Lett. 2009 Apr 8;276(1):47-52
pubmed: 19046800